history of confirmed or currently with the infection of sars-cov-2 prior to randomization; any prior administration of another investigational coronavirus vaccine or current/planned simultaneous participation in another interventional study to prevent or treat covid-19; known allergy to vaccines or vaccine ingredients, and serious adverse reactions to vaccines, such as urticaria, dyspnea, angioneurotic edema; serious chronic disease, serious cardiovascular disease, hypertension and diabetes that cannot be controlled by drugs, hepatorenal disease, malignant tumor, etc; acute central nervous system diseases such as encephalitis/myelitis, acute disseminating encephalomyelitis, and related disorders; receipt of blood/plasma products or immunoglobulins in the past 3 months before vaccination in this study; participation in other studies involving study intervention within 30 days prior to vaccination in this study; receipt of attenuated live vaccines in the past 14 days prior to vaccination in this study; receipt of inactivated or subunit vaccines in the past 7 days prior to vaccination in this study; acute exacerbation or presentation of stable chronic diseases (including but not limited to asthma, migraine, gastrointestinal disorder, etc.); acute febrile illness with axillary temperature >37.5°c on the day of vaccination; enrollment could be considered if the fever is absent for 72 hours prior to vaccination; according to the investigator's judgment, the participant has any other factors that might interfere with the results of the clinical trial or pose additional risk to the participant due to participation in the study.

history of confirmed or currently with the infection of sars-cov-2 prior to randomization; any prior administration of another investigational coronavirus vaccine or current/planned simultaneous participation in another interventional study to prevent or treat covid-19; known allergy to vaccines or vaccine ingredients, and serious adverse reactions to vaccines, such as urticaria, dyspnea, angioneurotic edema; serious chronic disease, serious cardiovascular disease, hypertension and diabetes that cannot be controlled by drugs, hepatorenal disease, malignant tumor, etc; acute central nervous system diseases such as encephalitis/myelitis, acute disseminating encephalomyelitis, and related disorders; receipt of blood/plasma products or immunoglobulins in the past 3 months before vaccination in this study; participation in other studies involving study intervention within 30 days prior to vaccination in this study; receipt of attenuated live vaccines in the past 14 days prior to vaccination in this study; receipt of inactivated or subunit vaccines in the past 7 days prior to vaccination in this study; acute exacerbation or presentation of stable chronic diseases (including but not limited to asthma, migraine, gastrointestinal disorder, etc.); acute febrile illness with axillary temperature >37.5°c on the day of vaccination; enrollment could be considered if the fever is absent for 72 hours prior to vaccination; according to the investigator's judgment, the participant has any other factors that might interfere with the results of the clinical trial or pose additional risk to the participant due to participation in the study.